Global drug maker Pfizer and biotech firm Amgen, each valued at more than HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing and aerial transport sectors set to sign agreements with the
Pfizer, Amgen among 22 strategic firms eyeing Hong Kong expansion: source
Oscar Liu,Olga Wong·South China Morning Post··1 min readLimited
S
Continue reading on South China Morning Post
This article was sourced from South China Morning Post's RSS feed. Visit the original for the complete story.
Limited free access — this source offers metered access before requiring a subscription.